NCT06448754 2026-02-20
eVOLVE-01
AstraZeneca
Phase 2 Recruiting
Clinical Trials
29 trialsNCT07098338 2026-02-05
LIBRA
AstraZeneca
Phase 2 Recruiting
NCT05071053 2025-08-22
CARMEN-GC01
Sanofi
Phase 2 Terminated
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04394624 2025-06-06
CARMEN-LC04
Sanofi
Phase 2 Terminated
NCT05311176 2025-05-11
nextHERIZON
Imugene Limited
Phase 2 Terminated
NCT05190445 2022-09-08
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Pieris Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT01515306 2022-03-08
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01246986 2021-01-12
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02443883 2020-06-29
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02831491 2020-06-09
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Withdrawn
NCT03704077 2020-05-19
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT01703091 2019-09-30
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01983878 2019-09-30
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00721162 2019-09-26
Study of Ramucirumab in Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01160744 2019-09-13
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
NCT01282463 2019-09-09
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01234402 2019-08-14
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Eli Lilly and Company
Phase 2 Completed
NCT01111604 2019-08-06
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01634555 2019-02-26
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
Phase 2 Completed
NCT01427933 2017-02-06
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01017731 2015-06-10
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Eli Lilly and Company
Phase 2 Completed
NCT00735696 2014-12-29
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01567163 2014-10-16
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT00627042 2014-10-08
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT01246960 2014-10-08
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00533702 2014-08-01
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Eli Lilly and Company
Phase 2 Completed
NCT00515697 2014-06-18
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT00862784 2014-06-17
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed